Detailed Narrative
Q1 FY26 Financial Performance and Segmental Contributions
Natco Pharma reported a consolidated total revenue of INR1,390.6 crores for Q1 FY26, a slight decrease from INR1,410.7 crores in the same period last year. EBITDA for the quarter was INR632.7 crores, achieving a robust margin of 45.5%, with a net profit of INR480.3 crores. The company's largest revenue contributor was formulation exports, including profit share and subsidiaries, at INR1,126.5 crores, while domestic formulation sales stood at INR107 crores. An interim dividend of INR2 per equity share was declared.
Impact of Revlimid and U.S. Pricing Pressure
The U.S. product portfolio experienced pricing pressure, primarily affecting Revlimid, which contributed to a dip in profitability. Management indicated that Revlimid's contribution remained consistent in Q1 but is expected to decline significantly post-September quarter, with most of its earnings for FY26 captured in the first half. While other U.S. products have remained stable, the ongoing decline of Revlimid is a key factor influencing the company's near-term outlook.
Strategic Diversification through Adcock Acquisition
Natco Pharma is actively diversifying its earnings base, notably through the acquisition of a 35.75% stake in Adcock, a South African pharmaceutical company. This transaction is anticipated to be completed within the next 2-3 months, subject to regulatory clearances. Adcock, with an annual PAT of approximately $47-48 million, is expected to contribute $15-17 million to Natco's consolidated PAT by FY27 and represent 15-25% of Natco's base earnings in the coming years, strengthening its presence in the African market.
Elevated R&D Investments and Future Pipeline
R&D expenses were notably higher in Q1 FY26 due to significant investments in high-value projects, particularly in cancer products requiring clinical trials and in the peptides and oligopeptide space. These elevated expenses are projected to continue into Q2 but are expected to decline in the December and March quarters of FY26. Annually, Natco typically files 7-8 products in the U.S., with 1-2 specifically in the oligo space, indicating a strategic focus on complex generics and novel entities.
Key Product Development Updates: Semaglutide and Risdiplam
The company is on track for the launch of Semaglutide in India, with market formation expected next year (FY27) following the completion of Phase I dosing and readout anticipated by November-December. For Risdiplam, Natco has completed preparations for launch and is awaiting a verdict from the Delhi High Court, with management expecting a decision 'any moment' in the next week or month. Both products represent significant future growth opportunities for the domestic market.
Crop Health Sciences Performance and Regulatory Outlook
The Crop Health Sciences segment reported sales of INR34.7 crores in Q1 FY26 and is nearing breakeven, with a full-year sales target of INR140-150 crores. Regarding regulatory matters, the Kothur facility, which received multiple USFDA observations, has submitted its responses in July, and management is cautiously optimistic about receiving a positive resolution within 90 days. The Mekaguda API facility has already received its EIR clearance.